{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:23:27Z","timestamp":1784193807221,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"25-26","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1 UL1 RR024150-01"],"award-info":[{"award-number":["1 UL1 RR024150-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI 33144"],"award-info":[{"award-number":["AI 33144"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI 48793"],"award-info":[{"award-number":["AI 48793"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.vaccine.2009.01.080","type":"journal-article","created":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T08:48:19Z","timestamp":1234255699000},"page":"3349-3358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine"],"prefix":"10.1016","volume":"27","author":[{"given":"Inna G.","family":"Ovsyannikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Vierkant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Shane","family":"Pankratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Poland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2009.01.080_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-3083.1985.tb01430.x","article-title":"Proportions of Ig classes and subclasses in rubella antibodies","volume":"21","author":"Sarnesto","year":"1985","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2009.01.080_bib2","first-page":"707","article-title":"Rubella vaccine","volume":"vol. 26","author":"Plotkin","year":"2004"},{"key":"10.1016\/j.vaccine.2009.01.080_bib3","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1016\/S0264-410X(00)00139-0","article-title":"Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland","volume":"18","author":"Davidkin","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.01.080_bib4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0264-410X(84)90043-4","article-title":"Persistence of rubella antibody 15 years after subcutaneous administration of Wistar 27\/3 strain live attenuated rubella virus vaccine","volume":"2","author":"Hillary","year":"1984","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.01.080_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0198-8859(94)90258-5","article-title":"Analysis of overlapping T- and B-cell antigenic sites on rubella virus E1 envelope protein. Influence of HLA-DR4 polymorphism on T-cell clonal recognition","volume":"39","author":"Ou","year":"1994","journal-title":"Hum Immunol"},{"issue":"18","key":"10.1016\/j.vaccine.2009.01.080_bib6","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/bioinformatics\/btm371","article-title":"Haplotype inference for present\u2013absent genotype data using previously identified haplotypes and haplotype patterns","volume":"23","author":"Yoo","year":"2007","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.vaccine.2009.01.080_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/gepi.10200","article-title":"On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles","volume":"23","author":"Morris","year":"2002","journal-title":"Genet Epidemiol"},{"issue":"5","key":"10.1016\/j.vaccine.2009.01.080_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1086\/500144","article-title":"Human leukocyte antigen haplotypes in the genetic control of immune response to measles\u2013mumps\u2013rubella vaccine","volume":"193","author":"Ovsyannikova","year":"2006","journal-title":"J Infect Dis"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2009.01.080_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002510050594","article-title":"Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism","volume":"50","author":"Sette","year":"1999","journal-title":"Immunogenetics"},{"issue":"16","key":"10.1016\/j.vaccine.2009.01.080_bib10","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2007.01.020","article-title":"HLA supertypes and immune responses to measles\u2013mumps\u2013rubella viral vaccine: findings and implications for vaccine design","volume":"25","author":"Ovsyannikova","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.01.080_bib11","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.humimm.2004.07.001","article-title":"The contribution of HLA class I antigens in immune status following two doses of rubella vaccination","volume":"65","author":"Ovsyannikova","year":"2004","journal-title":"Hum Immunol"},{"key":"10.1016\/j.vaccine.2009.01.080_bib12","series-title":"Handbook of ELISPOT: methods and protocols","first-page":"207","article-title":"Detection of measles virus-specific interferon-gamma-secreting T-cells by ELISPOT","author":"Ryan","year":"2005"},{"key":"10.1016\/j.vaccine.2009.01.080_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0952-7915(98)80124-6","article-title":"HLA supertypes and supermotifs: a functional perspective on HLA polymorphism","volume":"10","author":"Sette","year":"1998","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2009.01.080_bib14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0198-8859(01)00319-6","article-title":"Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules","volume":"62","author":"Sidney","year":"2001","journal-title":"Hum Immunol"},{"key":"10.1016\/j.vaccine.2009.01.080_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/338688","article-title":"Score tests for association between traits and haplotypes when linkage phase is ambiguous","volume":"70","author":"Schaid","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.vaccine.2009.01.080_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nm893","article-title":"Advantage of rare HLA supertype in HIV disease progression","volume":"9","author":"Trachtenberg","year":"2003","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2009.01.080_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0198-8859(99)00103-2","article-title":"Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules","volume":"60","author":"Livingston","year":"1999","journal-title":"Hum Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2009.01.080_bib18","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00705-008-0194-7","article-title":"MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30 years after vaccination","volume":"153","author":"Tang","year":"2008","journal-title":"Arch Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2009.01.080_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0167-5699(96)80542-1","article-title":"Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs","volume":"17","author":"Sidney","year":"1996","journal-title":"Immunol Today"},{"issue":"4","key":"10.1016\/j.vaccine.2009.01.080_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0952-7915(03)00083-9","article-title":"Epitope-based vaccines: an update on epitope identification, vaccine design and delivery","volume":"15","author":"Sette","year":"2003","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2009.01.080_bib21","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1517\/14712598.8.11.1659","article-title":"Personalized vaccines: the emerging field of vaccinomics","volume":"8","author":"Poland","year":"2008","journal-title":"Expert Opin Biol Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09001029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09001029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:15:56Z","timestamp":1759400156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09001029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":21,"journal-issue":{"issue":"25-26","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0264410X09001029"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.01.080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.01.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}